Cladribine Based Induction Therapy With All-Trans Retinoic Acid and Midostaurin in Relapsed/Refractory AML
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the investigational drug Midostaurin in various doses given with
ATRA and CLAG chemotherapy. Midostaurin is a FLT3 inhibitor that is activated or
overexpressed in a significant proportion of AML patients. Research has shown that
midostaurin and drugs like midostaurin may work better in combination with chemotherapy, like
CLAG. CLAG is a combination of cladribine, cytarabine, and G-CSF which is approved by the FDA
and used to treat AML.